Geron to Participate in 25th Annual Needham Virtual Healthcare Conference

Biopharmaceutical company to present on its first-in-class telomerase inhibitor for blood cancer treatment

Apr. 6, 2026 at 12:19pm

Got story updates? Submit your updates here. ›

Geron Corporation, a commercial-stage biopharmaceutical company focused on developing treatments for blood cancers, announced that members of its management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The live and archived audio webcast of the presentation will be available on Geron's website.

Why it matters

Geron's lead drug candidate, RYTELO (imetelstat), is a first-in-class telomerase inhibitor approved in the US and EU for treating certain adult patients with lower-risk myelodysplastic syndromes. The company is also conducting a pivotal Phase 3 trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, a serious and life-threatening blood cancer. Geron's participation in this high-profile healthcare conference provides an opportunity to update investors on its pipeline and commercial progress.

The details

The fireside chat at the Needham Virtual Healthcare Conference will take place on Monday, April 13, 2026 at 11:00 a.m. ET. Geron's management team will discuss the company's commercial and clinical development efforts, including the approval and launch of RYTELO and the ongoing Phase 3 trial in myelofibrosis. The webcast will be available through Geron's Investors & Media section of its website.

  • The fireside chat is scheduled for Monday, April 13, 2026 at 11:00 a.m. ET.
  • RYTELO (imetelstat) is approved in the United States and European Union for treating certain adult patients with lower-risk myelodysplastic syndromes.

The players

Geron Corporation

A commercial-stage biopharmaceutical company focused on developing treatments for blood cancers, including its first-in-class telomerase inhibitor RYTELO (imetelstat).

Got photos? Submit your photos here. ›

The takeaway

Geron's participation in the prestigious Needham Virtual Healthcare Conference highlights the company's progress in commercializing its first approved product, RYTELO, and advancing its pipeline of novel cancer therapies. Investors will be watching closely for updates on Geron's clinical development efforts and commercial launch plans.